Akeso’s HARMONi‑2 Trial Delivers 30‑Month OS Boost, Outpacing Pembrolizumab
Ivonescimab tops pembrolizumab in HARMONi‑2, boosting Akeso shares with 30‑month median overall survival and a 27% risk‑reduction in PD‑L1‑positive NSCLC.
3 minutes to read
AKESO INC
Akeso Inc. Sees Strategic Upswing With Landmark Cadonilimab Survival Data
Akeso Inc. boosts its outlook with 100 % 24‑month survival from cadonilimab in cervical cancer, positioning for Chinese approval and growth across solid tumours.
3 minutes to read
Akeso Inc’s Regulatory Wins Meet Market Skepticism Amidst Stock Volatility
Akeso Inc has received significant regulatory approvals for its cancer treatments, but faces market skepticism and volatility, with investors weighing the potential of its pipeline against commercialization challenges.
3 minutes to read
Akeso Inc. Celebrates FDA Approvals and Clinical Successes, Boosting Market Confidence
Akeso Inc. achieves significant milestones with FDA approvals and clinical successes, solidifying its position as a leader in the biopharmaceutical industry and driving its stock price to new highs.
3 minutes to read